Consider this pair:
vinBLAStinevinCRIStine
They look as if somebody lost an argument with the Shift key. The capital letters are deliberate. Vinblastine and vincristine are different drugs with dangerously similar names, so the typography is trying to make the difference harder to miss.
The technique is called tall man lettering. It appears on pharmacy labels, hospital screens and medication lists, usually as a suspicious patch of capitals in the middle of an otherwise well-behaved word. The FDA recommends it for selected look-alike names, including buPROPion and busPIRone, traMADol and traZODone, and predniSONE and prednisoLONE.
Capital letters as a speed bump
Reading is fast because we do not inspect every letter with equal care. We recognize familiar shapes, beginnings and endings, then let context finish the job. That efficiency becomes a liability when two long, unfamiliar names share most of their letters.
Tall man lettering changes the silhouette of the word. Instead of asking a tired clinician to notice the difference between hydralazine and hydroxyzine, it presents hydrALAZINE and hydrOXYzine. The capitals do not encode dosage or severity. They simply point at the part worth rereading.
The FDA began its name-differentiation project in 2001. It considers how similar a pair looks, the harm a mix-up could cause, reports of wrong-drug errors and other contributing factors. When tall man lettering seems appropriate, the agency can ask manufacturers to revise labels voluntarily. This is targeted typography, not a rule that every pharmaceutical name should resemble a ransom note.
The capitals have no separate pharmaceutical meaning. BLA is not a warning category, and CRI is not an instruction. The emphasis only makes sense beside the name it might be confused with. That is why the FDA publishes pairs and groups rather than a dictionary of capitalized syllables. A reader does not need to decode the typography; the hope is that the changed word shape interrupts a too-quick match.
A good idea with untidy evidence
One controlled test makes the idea look excellent. In a randomized simulation with 30 critical-care nurses, participants selected named drugs from sets of ten labeled syringes. The error rate was 5.3% without tall man lettering and 0.7% with it. Eye tracking showed that the capitals made nurses spend longer looking at the drug name and return to it more often. In this case, the design did not make reading effortless. It made a consequential word earn a little more attention.
That result is encouraging, but it came from 300 selections in a simulation, not from a hospital-wide tally of patient outcomes. The broader record is less tidy. A 2018 systematic review found that six studies reported lower error rates with tall man lettering while one reported a higher rate. Most of the evidence came from laboratory settings, and a hospital study found no effect on the rate of potential look-alike errors.
A 2026 review of 25 experiments reached a similarly cautious conclusion: the technique can help under some conditions, but results vary with drug familiarity, where the capitals appear, how long someone sees the label and whether the reader understands what the odd casing means. It is not strong enough to carry medication safety by itself.
That is the useful lesson hiding inside the ugly typography. Good safety design does not have to make error impossible to earn its place. Sometimes it adds a fraction of a second at exactly the right moment, then works alongside barcodes, prescribing context, careful storage and human checks.
The next time a drug name appears to have been attacked by a malfunctioning keyboard, the capitals may be doing a small, serious job: making two near-twins look less alike.